(Q45348074)

English

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

scientific article published on 17 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

13 December 2017

type 2 diabetes

0 references

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

T Heise

1

1 reference

Europe PubMed Central

13 December 2017

E Seewaldt-Becker

2

1 reference

Europe PubMed Central

13 December 2017

S Macha

3

1 reference

Europe PubMed Central

13 December 2017

S Hantel

4

1 reference

Europe PubMed Central

13 December 2017

S Pinnetti

5

1 reference

Europe PubMed Central

13 December 2017

L Seman

6

1 reference

Europe PubMed Central

13 December 2017

H J Woerle

7

1 reference

Europe PubMed Central

13 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 February 2013

1 reference

Europe PubMed Central

13 December 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

13 December 2017

15

1 reference

Europe PubMed Central

13 December 2017

7

1 reference

Europe PubMed Central

13 December 2017

613-621

1 reference

Europe PubMed Central

13 December 2017

Role of chronic and acute hyperglycemia in the development of diabetes complications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Management of diabetes across the course of disease: minimizing obesity-associated complications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Emerging treatment options for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Defining and achieving treatment success in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Dapagliflozin: more than just another oral glucose-lowering agent?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12073

21 January 2018

Identifiers

10.1111/DOM.12073

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45348074&oldid=2143924670"